Rose Duggan
Psychiatric/Mental Health · Buffalo, NYNPI 1285377184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,437 and has fallen 67.1% since, to $473 in 2025.
Across 133 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$567
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$541
- Johnson & Johnson$448
- Alkermes, Inc.$183
- Otsuka America Pharmaceutical, Inc.$173
- Axsome Therapeutics, Inc.$155
- plus $743 from 16 others
What the payments were for
- Food & beverage$2,74998%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $567 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $541 |
| Johnson & Johnson | 20 | $448 |
| Alkermes, Inc. | 9 | $183 |
| Otsuka America Pharmaceutical, Inc. | 9 | $173 |
| Axsome Therapeutics, Inc. | 6 | $155 |
| Corium, LLC | 5 | $122 |
| Lundbeck LLC | 4 | $93 |
| Idorsia Pharmaceuticals US Inc | 3 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $63 |
| Novo Nordisk | 3 | $52 |
| Noven Therapeutics, LLC | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Orexo US, Inc. | 3 | $46 |
| Indivior Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $29 |
| Biogen | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Braeburn Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $17 |
How this compares
$2,810 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 11 | $2,694 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $324 |
| Clomipramine Hcl | 11 | $308 |
| Propranolol Hcl ErPropranolol Hcl | 18 | $286 |
| Trazodone Hcl | 24 | $242 |
| Duloxetine Hcl | 18 | $176 |
| Haloperidol | 12 | $171 |
| Bupropion XlBupropion Hcl | 15 | $170 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $95 |
| Risperidone | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Buffalo
- Carl de FrancoBuffalo$28K
- Sarah OtwellBuffalo$15K
- Tisha TanyiBuffalo$10K
- Richard ZawislakBuffalo$10K
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.